Abstract
Comparative Study of Safety and Efficacy of Gabapentin Versus Amitriptyline in Patients With Painful Diabetic Peripheral Neuropathy, A Randomized open Label Parallel Group Study
Highlights
In type 2 diabetes, diabetic peripheral neuropathy (DPN) is one of the commonest causes of foot complications leading to pain, loss of sensation, foot ulcers and amputation leading to a reduced functional capacity of an individual[1]
In a study to determine the prevalence of foot ulcers and the incidence of amputations in patients with type 2 diabetes, Bruun C et al observed that after 19 years of diagnosis of type 2 diabetes, the incidence of amputations was still high in type 2 diabetes population[2]
This study revealed that gabapentin is safer and efficacious compared to amitriptyline in patients with painful diabetic peripheral neuropathy
Summary
In type 2 diabetes, DPN is one of the commonest causes of foot complications leading to pain, loss of sensation, foot ulcers and amputation leading to a reduced functional capacity of an individual[1]. It is clear that metabolism of nerve cells is altered by increased glucose level in blood. This results from the loss or damage to the sensory nerve fibres. The initial problem is loss of sensation for pain and this increases the likelihood of foot ulcers in the diabetic population. This accounts for recurrent hospitalization than other complications of type 2
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
